https://www.mayo.edu/research/clinical-trials/cls-20461640
A Study of Catequentinib, Anlotinib in Metastatic or Advanced Alveolar Soft Part Sarcoma,...
Learn more about services at Mayo Clinic.
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1490941/full
Frontiers | Radiotherapy combined with anlotinib for refractory leiomyosarcoma: a case report and...
Refractory leiomyosarcoma (LMS) is characterized by notoriously high recurrence rates and poses significant surgical challenges due to its anatomical complex...
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1476205/full
Frontiers | Penpulimab and Anlotinib in PDL1 high-expression pulmonary giant cell carcinoma with...
Pulmonary giant cell carcinoma (PGCC) is a rare subtype of non-small cell lung cancer (NSCLC) characterized by complex pathology, high rates of misdiagnosis ...
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1507281/full
Frontiers | Efficacy of anlotinib and chemotherapy combination as neoadjuvant therapy in the...
Pulmonary arterial intimal sarcoma (PAIS) is a rare malignant mesenchymal tumor often associated with an unfavorable prognosis and lacks a standardized treat...
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1122294/full
Frontiers | A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the...
Background: Anlotinib is a novel oral small-molecule tyrosine kinase inhibitor (TKI), which can inhibit angiogenesis. The purpose of this study was to evalua...
phase ii clinical trial
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1232858/full
Frontiers | Efficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as an...
Background:The efficacy of current adjuvant chemotherapy for gastric adenocarcinoma/gastroesophageal junction adenocarcinoma (GA/GEJA) leaves much to be desi...
efficacy and safety
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1113389/full
Frontiers | Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma...
OBJECTIVE: Exposing tumor antigens to the immune system is the key to ensuring the efficacy of immunotherapy. SBRT is the main way to reveal the specifical a...
frontierstoripalimabcombinationanlotinibunresectable